Research Progress in microRNA-Based Therapy for Gastric Cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Van CE, Sagaert X, Topal B, et al. Gastric cancer. Lancet. 2016;388(60):2654–2664. doi:10.1016/S0140-6736(16)30354-327156933
   PubMedGoogle Scholar
• Orditura M, Galizia G, Sforza V, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635–1649. doi:10.3748/wjg.v20.i7.163524587643
   PubMed Web of Science ®Google Scholar
• Murahashi S, Takahari D, Wakatsuki T, et al. A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. Int J Clin Oncol. 2018;23(1):92–97. doi:10.1007/s10147-017-1192-028913565
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van CE, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X20728210
   PubMed Web of Science ®Google Scholar
• Chen Z, Li Z, Soutto M, et al. Integrated analysis of mouse and human gastric neoplasms identifies conserved microRNA networks in gastric carcinogenesis. Gastroenterology. 2019;156(4):1127–1139. doi:10.1053/j.gastro.2018.11.05230502323
   PubMed Web of Science ®Google Scholar
• Miroshnichenko S, Patutina O. Enhanced inhibition of tumorigenesis using combinations of miRNA-targeted therapeutics. Front Pharmacol. 2019;10:488. doi:10.3389/fphar.2019.0048831156429
   PubMed Web of Science ®Google Scholar
• Zhang JX, Xu Y, Gao Y, et al. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer. 2017;16(1):18.28114937
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang H, Bai M, et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer. Mol Ther. 2018;26(3):774–783. doi:10.1016/j.ymthe.2018.01.00129456019
   PubMed Web of Science ®Google Scholar
• Song Z, Liang X, Wang Y, et al. Phenylboronic acid-functionalized polyamidoamine-mediated miR-34a delivery for the treatment of gastric cancer. Biomater Sci. 2019;7(4):1632–1642. doi:10.1039/C8BM01385C30720809
   PubMed Web of Science ®Google Scholar
• Hu N, Yin JF, Ji Z, et al. Strengthening gastric cancer therapy by trastuzumab-conjugated nanoparticles with simultaneous encapsulation of anti-miR-21 and 5-fluorouridine. Cell Physiol Biochem. 2017;44(6):2158–2173. doi:10.1159/00048595529241186
   PubMedGoogle Scholar
• Jiang L, Yang W, Bian W, et al. MicroRNA-623 targets cyclin D1 to inhibit cell proliferation and enhance the chemosensitivity of cells to 5-fluorouracil in gastric cancer. Oncol Res. 2018;27(1):19–27. doi:10.3727/096504018X1519346924050829495973
   PubMed Web of Science ®Google Scholar
• Zhu P, Zhang J, Zhu J, et al. MiR-429 induces gastric carcinoma cell apoptosis through Bcl-2. Cell Physiol Biochem. 2015;37(4):1572–1580. doi:10.1159/00043852426513239
   PubMedGoogle Scholar
• Li LQ, Pan D, Chen Q, et al. Sensitization of gastric cancer cells to 5-FU by microRNA-204 through targeting the TGFBR2-mediated epithelial to mesenchymal transition. Cell Physiol Biochem. 2018;47(4):1533–1545. doi:10.1159/00049087129940566
   PubMedGoogle Scholar
• Xie L, Zhang Z, Tan Z, et al. MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. Mol Cell Biochem. 2014;392(1–2):153–159. doi:10.1007/s11010-014-2028-024658854
   PubMed Web of Science ®Google Scholar
• Sun KK, Shen XJ, Yang D, et al. MicroRNA-31 triggers G2/M cell cycle arrest, enhances the chemosensitivity and inhibits migration and invasion of human gastric cancer cells by downregulating the expression of zeste homolog 2 (ZH2). Archi Biochem Biophys. 2019;663:269–275. doi:10.1016/j.abb.2019.01.023
   PubMed Web of Science ®Google Scholar
• Korourian A, Roudi R, Shariftabrizi A, et al. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med (Maywood). 2017;242(18):1842–1847. doi:10.1177/153537021772846028836853
   PubMed Web of Science ®Google Scholar
• Korourian A, Madjd Z, Roudi R, et al. Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma. Bratisl Lek Listy. 2019;120(1):35–39. doi:10.4149/BLL_2019_00530685990
   PubMed Web of Science ®Google Scholar
• Yu C, Chen DQ, Liu HX, et al. Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p. Biomed Pharmacother. 2019;109:2327–2334. doi:10.1016/j.biopha.2018.10.06130551491
   PubMed Web of Science ®Google Scholar
• Jian B, Li Z, Xiao D, et al. Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene. Tumour Biol. 2016;37(7):8941–8949. doi:10.1007/s13277-015-4727-x26753960
   PubMed Web of Science ®Google Scholar
• Shen J, Niu W, Zhang H, et al. Downregulation of microRNA-147 inhibits cell proliferation and increases the chemosensitivity of gastric cancer cells to 5-fluorouracil by directly targeting PTEN. Oncol Res. 2018;26(6):901–911. doi:10.3727/096504017X1506190253371528950928
   PubMed Web of Science ®Google Scholar
• Ge X, Liu X, Lin F, et al. MicroRNA-421 regulated by HIF-1alpha promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget. 2016;7(17):24466–24482. doi:10.18632/oncotarget.822827016414
   PubMed Web of Science ®Google Scholar
• Ge X, Cui H, Zhou Y, et al. MiR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med Rep. 2017;16(6):9664–9670. doi:10.3892/mmr.2017.781929152656
   PubMed Web of Science ®Google Scholar
• Xie X, Huang N, Zhang Y, et al. MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells. J Cancer. 2019;10(4):1039–1051. doi:10.7150/jca.2581430854110
   PubMed Web of Science ®Google Scholar
• Zhao J, Nie Y, Wang H, et al. MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin. Gene. 2016;576(2 Pt 2):828–833. doi:10.1016/j.gene.2015.11.01326589846
   PubMed Web of Science ®Google Scholar
• Li B, Wang W, Li Z, et al. MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett. 2017;410:212–227. doi:10.1016/j.canlet.2017.09.03528965855
   PubMed Web of Science ®Google Scholar
• Han X, Zhang JJ, Han ZQ, et al. Let-7b attenuates cisplatin resistance and tumor growth in gastric cancer by targeting AURKB. Cancer Gene Ther. 2018;25(11–12):300–308. doi:10.1038/s41417-018-0048-830237418
   PubMed Web of Science ®Google Scholar
• Zhou J, Chen Q. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway. FASEB J. 2019;33(3):3420–3436. doi:10.1096/fj.201800618RRR30576232
   PubMed Web of Science ®Google Scholar
• Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36(1):53. doi:10.1186/s13046-017-0528-y28407783
   PubMed Web of Science ®Google Scholar
• Zhi X, Tao J, Xiang G, et al. APRIL induces cisplatin resistance in gastric cancer cells via activation of the NF-κB pathway. Cell Physiol Biochem. 2015;35(2):571–585. doi:10.1159/00036972025612651
   PubMedGoogle Scholar
• Zhang Z, Kong Y, Yang W, et al. MicroRNA-218 enhances gastric cancer cell cisplatin sensitivity by targeting survivin. Exp Ther Med. 2018;16(6):4796–4802. doi:10.3892/etm.2018.680230542435
   PubMed Web of Science ®Google Scholar
• Zhang XL, Shi HJ, Wang JP, et al. MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol. 2014;20(32):11347–11355. doi:10.3748/wjg.v20.i32.1134725170221
   PubMed Web of Science ®Google Scholar
• Jiang T, Dong P, Li L, et al. MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells. Oncol Rep. 2017;38(1):151–158. doi:10.3892/or.2017.565928534959
   PubMed Web of Science ®Google Scholar
• Ghasabi M, Majidi J, Mansoori B, et al. The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration. J Cell Physiol. 2019. doi:10.1002/jcp.28823
   Web of Science ®Google Scholar
• Huang X, Li Z, Zhang Q, et al. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019;18(1):71. doi:10.1186/s12943-019-0969-330927924
   PubMed Web of Science ®Google Scholar
• Gu J, Li X, Li H, et al. MicroRNA-198 inhibits proliferation and induces apoptosis by directly suppressing FGFR1 in gastric cancer. Biosci Rep. 2019;39:6. doi:10.1042/BSR20181258
   Web of Science ®Google Scholar
• Cao W, Yang W, Fan R, et al. MiR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol. 2014;35(2):1287–1295. doi:10.1007/s13277-013-1171-724068565
   PubMedGoogle Scholar
• Cheng C, Qin Y, Zhi Q, et al. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107(Pt B):2620–2629. doi:10.1016/j.ijbiomac.2017.10.15429080815
   PubMedGoogle Scholar
• Zhang Z, Kong Y, Yang W, et al. Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncol Rep. 2016;36(4):2391–2397. doi:10.3892/or.2016.501627513895
   PubMed Web of Science ®Google Scholar
• Yan R, Li K, Yuan DW, et al. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1. Int J Oncol. 2018;53(6):2566–2578. doi:10.3892/ijo.2018.459530320337
   PubMed Web of Science ®Google Scholar
• Zhou N, Qu Y, Xu C, et al. Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Exp Ther Med. 2016;11(2):625–630. doi:10.3892/etm.2015.292026893657
   PubMed Web of Science ®Google Scholar
• Chen Z, Gao YJ, Hou RZ, et al. MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(1):171–180.
   Web of Science ®Google Scholar
• Shao L, Chen Z, Soutto M, et al. Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer. FASEB J. 2019;33(1):264–274. doi:10.1096/fj.201701456RR29985646
   PubMed Web of Science ®Google Scholar
• Yan J, Dang Y, Liu S, et al. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol. 2016;37(12):16345–16355. doi:10.1007/s13277-016-5448-5
   Google Scholar
• Fang Y, Shen H, Li H, et al. MiR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013;45(11):963–972. doi:10.1093/abbs/gmt10624108762
   PubMed Web of Science ®Google Scholar
• Xin L, Yang WF, Zhang HT, et al. The mechanism study of lentiviral vector carrying methioninase enhances the sensitivity of drug-resistant gastric cancer cells to Cisplatin. Br J Cancer. 2018;118(9):1189–1199. doi:10.1038/s41416-018-0043-829576621
   PubMed Web of Science ®Google Scholar
• Yang SM, Huang C, Li XF, et al. MiR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013;306:162–168. doi:10.1016/j.tox.2013.02.01423466500
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhou X, Du Y, et al. MiR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. Mol Med Rep. 2016;14(2):1742–1750. doi:10.3892/mmr.2016.541327357419
   PubMed Web of Science ®Google Scholar
• Lu C, Shan Z, Li C, et al. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother. 2017;86:450–456. doi:10.1016/j.biopha.2016.11.13928012924
   PubMed Web of Science ®Google Scholar
• Du X, Liu B, Luan X, et al. MiR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy. Exp Ther Med. 2018;15(1):599–605. doi:10.3892/etm.2017.535429375703
   PubMed Web of Science ®Google Scholar
• Yang M, Shan X, Zhou X, et al. MiR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem. 2014;14(6):884–891. doi:10.2174/187152061466614052816131824875127
   PubMed Web of Science ®Google Scholar
• Zhuang M, Shi Q, Zhang X, et al. Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2. Tumour Biol. 2015;36(4):2737–2745. doi:10.1007/s13277-014-2898-525492481
   PubMedGoogle Scholar
• Xue M, Li G, Fang X, et al. hsa_circ_0081143 promotes cisplatin resistance in gastric cancer by targeting miR-646/CDK6 pathway. Cancer Cell Int. 2019;19:25. doi:10.1186/s12935-019-0737-x30733646
   PubMed Web of Science ®Google Scholar
• Xi Z, Si J, Nan J. LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA-30b/autophagy-related gene 5 axis in gastric cancer. Int J Oncol. 2019;54(1):239–248. doi:10.3892/ijo.2018.460930365113
   PubMed Web of Science ®Google Scholar
• Li Y, Lv S, Ning H, et al. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed Pharmacother. 2018;108:1775–1782.30372881
   PubMed Web of Science ®Google Scholar
• Peng QP, Du DB, Ming Q, et al. MicroRNA 494 increases chemosensitivity to doxorubicin in gastric cancer cells by targeting phosphodiesterases 4D. Cell Mol Biol (Noisy-Le-Grand). 2018;64(15):62–66. doi:10.14715/cmb/2017.64.15.10
   PubMed Web of Science ®Google Scholar
• Zhou Z, Lin Z, He Y, et al. The long noncoding RNA D63785 regulates chemotherapy sensitivity in human gastric cancer by targeting miR-422a. Mol Ther Nucleic Acids. 2018;12:405–419. doi:10.1016/j.omtn.2018.05.02430195778
   PubMedGoogle Scholar
• Zou J, Xu Y. MicroRNA-140 inhibits cell proliferation in gastric cancer cell line HGC-27 by suppressing SOX4. Med Sci Monit. 2016;22:2243–2252. doi:10.12659/MSM.89663327353653
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qu X, Li C, et al. MiR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol. 2015;36(4):2277–2285. doi:10.1007/s13277-014-2835-725407491
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhang Y and Song L. MiR-16-1 targeted silences far upstream element binding protein 1 to advance the chemosensitivity to adriamycin in gastric cancer. Pathol Oncol Res. 2018;24(3):483–488. doi:10.1007/s12253-017-0263-x28667493
   PubMed Web of Science ®Google Scholar
• Liu X, Lu Y, Xu Y, et al. Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019;459:122–134. doi:10.1016/j.canlet.2019.05.03531173853
   PubMed Web of Science ®Google Scholar
• Xu YC, Liu X, Li M, et al. A novel mechanism of doxorubicin resistance and tumorigenesis mediated by MicroRNA-501-5p-Suppressed BLID. Mol Ther Nucleic Acids. 2018;12:578–590. doi:10.1016/j.omtn.2018.06.01130195794
   PubMedGoogle Scholar
• Chen J, Zhou C, Li J, et al. MiR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. Int J Mol Med. 2018;41(4):1855–1866. doi:10.3892/ijmm.2018.340529393355
   PubMed Web of Science ®Google Scholar
• Jin B, Liu Y, Wang H. Antagonism of miRNA-21 sensitizes human gastric cancer cells to paclitaxel. Cell Biochem Biophys. 2015;72(1):275–282. doi:10.1007/s12013-014-0450-227040946
   PubMed Web of Science ®Google Scholar
• Wang M, Qiu R, Yu S, et al. Paclitaxel-resistant gastric cancer MGC-803 cells promote epithelial-to-mesenchymal transition and chemoresistance in paclitaxel-sensitive cells via exosomal delivery of miR-155-5p. Int J Oncol. 2019;54(1):326–338. doi:10.3892/ijo.2018.460130365045
   PubMed Web of Science ®Google Scholar
• Wu H, Huang M, Lu M, et al. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol. 2013;71(5):1159–1171. doi:10.1007/s00280-013-2108-y23423488
   PubMed Web of Science ®Google Scholar
• Wu X, Zheng Y, Han B, et al. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother. 2018;99:832–838. doi:10.1016/j.biopha.2018.01.13029710482
   PubMed Web of Science ®Google Scholar
• Yan LH, Chen ZN, Li L, et al. MiR-135a promotes gastric cancer progression and resistance to oxaliplatin. Oncotarget. 2016;7(43):70699–70714. doi:10.18632/oncotarget.1220827683111
   PubMedGoogle Scholar
• Zhao Q, Li Y, Tan BB, et al. HIF-1α induces multidrug resistance in gastric cancer cells by inducing miR-27a. PLoS One. 2015;10(8):e0132746. doi:10.1371/journal.pone.013274626292288
   PubMedGoogle Scholar
• Cao W, Wei W, Zhan Z, et al. MiR-1284 modulates multidrug resistance of gastric cancer cells by targeting EIF4A1. Oncol Rep. 2016;35(5):2583–2591. doi:10.3892/or.2016.464326936591
   PubMed Web of Science ®Google Scholar
• Cao W, Wei W, Zhan Z, et al. Regulation of drug resistance and metastasis of gastric cancer cells via the microRNA647-ANK2 axis. Int J Mol Med. 2018;41(4):1958–1966. doi:10.3892/ijmm.2018.338129328428
   PubMed Web of Science ®Google Scholar
• Liu X, Du P, Han L, et al. Effects of miR-200a and FH535 combined with taxol on proliferation and invasion of gastric cancer. Pathol Res Pract. 2018;214(3):442–449. doi:10.1016/j.prp.2017.12.00429482988
   PubMed Web of Science ®Google Scholar
• Tian L, Zhao Z, Xie L, et al. MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget. 2018;9(4):4886–4896. doi:10.18632/oncotarget.2351329435149
   PubMedGoogle Scholar
• Shang Y, Zhang Z, Liu Z, et al. MiR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014;33(25):3267–3276. doi:10.1038/onc.2013.29723893241
   PubMed Web of Science ®Google Scholar
• Shang Y, Feng B, Zhou L, et al. The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer. Oncotarget. 2016;7(1):538–549. doi:10.18632/oncotarget.v7i126623719
   PubMedGoogle Scholar
• An Y, Zhang Z, Shang Y, et al. MiR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015;6:e1766. doi:10.1038/cddis.2015.12325996293
   PubMed Web of Science ®Google Scholar
• YiRen H, YingCong Y, Sunwu Y, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16(1):174. doi:10.1186/s12943-017-0743-329162158
   PubMed Web of Science ®Google Scholar
• Shen B, Yu S, Zhang Y, et al. MiR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway. Onco Targets Ther. 2016;9:6009–6019. doi:10.2147/OTT27757042
   PubMed Web of Science ®Google Scholar
• Eto K, Iwatsuki M, Watanabe M, et al. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Int J Cancer. 2015;136(7):1537–1545. doi:10.1002/ijc.v136.725159729
   PubMed Web of Science ®Google Scholar
• Zhou X, Men X, Zhao R, et al. MiR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer. Cancer Gene Ther. 2018;25(3–4):68–76. doi:10.1038/s41417-017-0005-y29302045
   PubMed Web of Science ®Google Scholar
• Eto K, Iwatsuki M, Watanabe M, et al. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol. 2014;21(1):343–350. doi:10.1245/s10434-013-3325-724154840
   PubMed Web of Science ®Google Scholar
• Sui M, Jiao A, Zhai H, et al. Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer. Exp Ther Med. 2017;14(1):657–663. doi:10.3892/etm.2017.454828672982
   PubMed Web of Science ®Google Scholar
• Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 2011;17(9):2725–2733. doi:10.1158/1078-0432.CCR-10-213221220473
   PubMed Web of Science ®Google Scholar
• Yu Y, Yu X, Liu H, et al. MiR-494 inhibits cancer-initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2-positive gastric cancer. Int J Mol Med. 2018;42(2):998–1007. doi:10.3892/ijmm.2018.368029786108
   PubMed Web of Science ®Google Scholar
• Venturutti L, Cordo RR, Rivas MA, et al. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene. 2016;35(48):6189–6202. doi:10.1038/onc.2016.15127157613
   PubMed Web of Science ®Google Scholar
• Jang E, Kim E, Son HY, et al. Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy. Biomaterials. 2016;105:12–24. doi:10.1016/j.biomaterials.2016.07.03627497057
   PubMed Web of Science ®Google Scholar
• Li T, Zhang Y, Meng YP, et al. MiR-542-3p appended sorafenib/all-trans retinoic acid (ATRA)-loaded lipid nanoparticles to enhance the anticancer efficacy in gastric cancers. Pharm Res. 2017;34(12):2710–2719. doi:10.1007/s11095-017-2202-729181687
   PubMed Web of Science ®Google Scholar
• Liu Q, Li RT, Qian HQ, et al. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials. 2013;34(29):7191–7203. doi:10.1016/j.biomaterials.2013.06.00423806972
   PubMed Web of Science ®Google Scholar
• Wu FL, Zhang J, Li W, et al. Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer. Oncotarget. 2017;8(40):67189–67202. doi:10.18632/oncotarget.1806628978026
   PubMedGoogle Scholar
• Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659. doi:10.1038/ncb159617486113
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396–405. doi:10.1016/j.jconrel.2015.07.03026241750
   PubMed Web of Science ®Google Scholar
• Fan Y, Che X, Hou K, et al. MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression. Exp Cell Res. 2018;373(1–2):180–187. doi:10.1016/j.yexcr.2018.10.01130367831
   PubMed Web of Science ®Google Scholar
• Polakovicova I, Jerez S, Wichmann IA, et al. Role of microRNAs and exosomes in helicobacter pylori and epstein-barr virus associated gastric cancers. Front Microbiol. 2018;9:636. doi:10.3389/fmicb.2018.0063629675003
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Suzuki H. Role of MicroRNAs-221/222 in digestive systems. J Clin Med. 2015;4(8):1566–1577. doi:10.3390/jcm408156626258795
   PubMed Web of Science ®Google Scholar
• Xie M, Dart DA, Owen S, et al. Insights into roles of the miR-1, −133 and −206 family in gastric cancer (Review). Oncol Rep. 2016;36(3):1191–1198. doi:10.3892/or.2016.490827349337
   PubMed Web of Science ®Google Scholar
• Shen Z, Li Y, Zhao C, et al. MiR-494-BAG-1 axis is involved in cinobufacini-induced cell proliferation and apoptosis in gastric cancer. Mol Med Rep. 2018;17(5):7435–7441. doi:10.3892/mmr.2018.878829568970
   PubMed Web of Science ®Google Scholar
• Zhou RP, Chen G, Shen ZL, et al. Cinobufacin suppresses cell proliferation via miR-494 in BGC-823 gastric cancer cells. Asian Pac J Cancer Prev. 2014;15(3):1241–1245. doi:10.7314/APJCP.2014.15.3.124124606447
   PubMedGoogle Scholar
• Mikami J, Kurokawa Y, Takahashi T, et al. Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study. Gastric Cancer. 2016;19(3):817–826. doi:10.1007/s10120-015-0556-226486505
   PubMed Web of Science ®Google Scholar
• Jia X, Li N, Peng C, et al. MiR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells. Oncotarget. 2016;7(6):7044–7054. doi:10.18632/oncotarget.v7i626799283
   PubMed Web of Science ®Google Scholar
• Ye Y, Fang Y, Xu W, et al. 3,3ʹ-Diindolylmethane induces anti-human gastric cancer cells by the miR-30e-ATG5 modulating autophagy. Biochem Pharmacol. 2016;115:77–84. doi:10.1016/j.bcp.2016.06.01827372603
   PubMed Web of Science ®Google Scholar
• Cao D, Jiang J, Tsukamoto T, et al. Canolol inhibits gastric tumors initiation and progression through COX-2/PGE2 pathway in K19-C2mE transgenic mice. PLoS One. 2015;10(3):e0120938. doi:10.1371/journal.pone.012093825781635
   PubMed Web of Science ®Google Scholar
• Xu S, Li D, Li T, et al. MiR-494 sensitizes gastric cancer cells to TRAIL treatment through downregulation of survivin. Cell Physiol Biochem. 2018;51(5):2212–2223. doi:10.1159/00049586730537730
   PubMedGoogle Scholar
• Wang X, Li Y, Dai Y, et al. Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124/IL-6R/STAT3 axis. Sci Rep. 2016;6:36796. doi:10.1038/srep3679627824145
   PubMed Web of Science ®Google Scholar
• Zheng YB, Xiao GC, Tong SL, et al. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol. 2015;21(23):7197–7207. doi:10.3748/wjg.v21.i23.719726109806
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ding BZ, Lin YP, et al. MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. Gene. 2018;644:56–65. doi:10.1016/j.gene.2017.10.04629054762
   PubMed Web of Science ®Google Scholar
• Wu H, Huang M, Liu Y, et al. Luteolin Induces apoptosis by up-regulating miR-34a in human gastric cancer cells. Technol Cancer Res Treat. 2015;14(6):747–755. doi:10.7785/tcrt.2012.50043424988056
   PubMed Web of Science ®Google Scholar
• Wang G, Liu G, Ye Y, et al. Upregulation of miR-34a by diallyl disulfide suppresses invasion and induces apoptosis in SGC-7901 cells through inhibition of the PI3K/Akt signaling pathway. Oncol Lett. 2016;11(4):2661–2667. doi:10.3892/ol.2016.426627073535
   PubMed Web of Science ®Google Scholar
• Mohammadian F, Abhari A, Dariushnejad H, et al. Upregulation of mir-34a in AGS gastric cancer cells by a PLGA-PEG-PLGA chrysin nano formulation. Asian Pac J Cancer Prev. 2015;16(18):8259–8263. doi:10.7314/APJCP.2015.16.18.825926745070
   PubMedGoogle Scholar
• Li H, Cheng J, Mao Y, et al. MiR-21 inhibits the effects of cyclooxygenase-2 inhibitor NS398 on apoptosis and invasion in gastric cancer cells. Onco Targets Ther. 2015;8:3245–3253. doi:10.2147/OTT.S9001226604791
   PubMed Web of Science ®Google Scholar
• Yao SS, Han L, Tian ZB, et al. Celastrol inhibits growth and metastasis of human gastric cancer cell MKN45 by down-regulating microRNA-21. Phytother Res. 2019;33(6):1706–1716. doi:10.1002/ptr.635930989726
   PubMed Web of Science ®Google Scholar
• Zhang W, Tan Y, Ma H. Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation. Oncol Lett. 2017;14(5):5409–5417. doi:10.3892/ol.2017.685829142602
   PubMed Web of Science ®Google Scholar
• Kiani S, Akhavan-Niaki H, Fattahi S, et al. Purified sulforaphane from broccoli (Brassica oleracea var. italica) leads to alterations of CDX1 and CDX2 expression and changes in miR-9 and miR-326 levels in human gastric cancer cells. Gene. 2018;678:115–123. doi:10.1016/j.gene.2018.08.02630096452
   PubMed Web of Science ®Google Scholar
• Mohammadian F, Pilehvar SY, Zarghami F, et al. Upregulation of miR-9 and Let-7a by nanoencapsulated chrysin in gastric cancer cells. Artif Cells Nanomed Biotechnol. 2017;45(6):1–6. doi:10.1080/21691401.2017.1391824
   PubMed Web of Science ®Google Scholar
• Ma L. Teruya FJ and Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–688. doi:10.1038/nature0617417898713
   PubMed Web of Science ®Google Scholar
• Wang J, Xue X, Hong H, et al. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9. Oncotarget. 2017;8(1):574–582. doi:10.18632/oncotarget.1347927880941
   PubMedGoogle Scholar
• Lee SD, Yu D, Lee DY, et al. Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells. Cancer Sci. 2019;110(2):662–673. doi:10.1111/cas.1389430485589
   PubMed Web of Science ®Google Scholar
• Li X, Liang J, Liu YX, et al. MiR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1. Pharmazie. 2016;71(11):640–643. doi:10.1691/ph.2016.669629441968
   PubMed Web of Science ®Google Scholar
• Ning J, Jiao Y, Xie X, et al. MiR-138-5p modulates the expression of excision repair cross-complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin. Oncol Rep. 2019;41(2):1131–1139. doi:10.3892/or.2018.690730535472
   PubMed Web of Science ®Google Scholar
• Yu L, Zhou GQ, Li DC. MiR-136 triggers apoptosis in human gastric cancer cells by targeting AEG-1 and BCL2. Eur Rev Med Pharmacol Sci. 2018;22(21):7251–7256. doi:10.26355/eurrev_201811_1625930468468
   PubMed Web of Science ®Google Scholar
• Zhang X, Yao J, Guo K, et al. The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin. Oncotarget. 2018;9(2):2105–2119. doi:10.18632/oncotarget.2324929416757
   PubMedGoogle Scholar
• Zhang Y, Xu W, Ni P, et al. MiR-99a and miR-491 regulate cisplatin resistance in human gastric cancer cells by targeting CAPNS1. Int J Biol Sci. 2016;12(12):1437–1447. doi:10.7150/ijbs.1652927994509
   PubMed Web of Science ®Google Scholar
• Wang LL, Zhang XH, Zhang X, et al. MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT). Eur Rev Med Pharmacol Sci. 2016;20(9):1733–1739.27212164
   PubMed Web of Science ®Google Scholar
• Wen L, Cheng F, Zhou Y, et al. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J Gastroenterol. 2015;21(5):313–319. doi:10.4103/1319-3767.16620626458859
   PubMed Web of Science ®Google Scholar
• He J, Qi H, Chen F, et al. MicroRNA-25 contributes to cisplatin resistance in gastric cancer cells by inhibiting forkhead box O3a. Oncol Lett. 2017;14(5):6097–6102. doi:10.3892/ol.2017.698229113252
   PubMed Web of Science ®Google Scholar
• Qian X, Xu W, Xu J, et al. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer. Oncotarget. 2017;8(29):47691–47708. doi:10.18632/oncotarget.v8i2928548950
   PubMedGoogle Scholar
• Xu N, Lian YJ, Dai X, et al. MiR-7 increases cisplatin sensitivity of gastric cancer cells through suppressing mTOR. Technol Cancer Res Treat. 2017;16(6):1022–1030.
   PubMed Web of Science ®Google Scholar
• Huang H, Tang J, Zhang L, et al. MiR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1. Int J Oncol. 2018;53(6):2769–2779. doi:10.3892/ijo.2018.459330320370
   PubMed Web of Science ®Google Scholar
• Pang X, Zhou Z, Yu Z, et al. Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain. RNA Biol. 2019;16(2):233–248. doi:10.1080/15476286.2019.156566530628514
   PubMed Web of Science ®Google Scholar
• Zhang F, Li K, Yao X, et al. A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer. EBioMedicine. 2019;44:311–321. doi:10.1016/j.ebiom.2019.05.00331078520
   PubMed Web of Science ®Google Scholar
• Li N, Han M, Zhou N, et al. MicroRNA-495 confers increased sensitivity to chemotherapeutic agents in gastric cancer via the Mammalian Target of Rapamycin (mTOR) signaling pathway by interacting with human Epidermal Growth Factor Receptor 2 (ERBB2). Med Sci Monit. 2018;24:5960–5972. doi:10.12659/MSM.90945830147110
   PubMed Web of Science ®Google Scholar
• Zhang PF, Sheng LL, Wang G, et al. MiR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget. 2016;7(23):35284–35292. doi:10.18632/oncotarget.916927167197
   PubMedGoogle Scholar
• Wang H, Qin R, Guan A, et al. HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression. J Cell Biochem. 2018;119(9):7226–7234. doi:10.1002/jcb.v119.929856087
   PubMed Web of Science ®Google Scholar
• Chang L, Guo F, Wang Y, et al. MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE. Pathol Oncol Res. 2014;20(1):93–98. doi:10.1007/s12253-013-9664-723821457
   PubMed Web of Science ®Google Scholar
• Nie H, Mu J, Wang J, et al. MiR-195-5p regulates multidrug resistance of gastric cancer cells via targeting ZNF139. Oncol Rep. 2018;40(3):1370–1378. doi:10.3892/or.2018.652429956811
   PubMed Web of Science ®Google Scholar
• Tan B, Li Y, Zhao Q, et al. ZNF139 increases multidrug resistance in gastric cancer cells by inhibiting miR-185. Biosci Rep. 2018;38:5. doi:10.1042/BSR20181023
   Web of Science ®Google Scholar
• Zhu W, Shan X, Wang T, et al. MiR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127(11):2520–2529. doi:10.1002/ijc.2526020162574
   PubMed Web of Science ®Google Scholar
• Wang P, Li Z, Liu H, et al. MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun. 2016;479(1):91–96. doi:10.1016/j.bbrc.2016.09.04027622325
   PubMed Web of Science ®Google Scholar
• Teng R, Hu Y, Zhou J, et al. Overexpression of Lin28 decreases the chemosensitivity of gastric cancer cells to oxaliplatin, paclitaxel, doxorubicin, and fluorouracil in part via microRNA-107. PLoS One. 2015;10(12):e0143716. doi:10.1371/journal.pone.014371626636340
   PubMed Web of Science ®Google Scholar
• Bao J, Xu Y, Wang Q, et al. MiR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomed Pharmacother. 2017;92:1030–1037. doi:10.1016/j.biopha.2017.06.01128609840
   PubMed Web of Science ®Google Scholar
• Lang C, Xu M, Zhao Z, et al. MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1. Oncol Lett. 2018;16(3):4020–4026. doi:10.3892/ol.2018.912230128023
   PubMed Web of Science ®Google Scholar
• Yang X, Zhao Q, Yin H, et al. MiR-33b-5p sensitizes gastric cancer cells to chemotherapy drugs via inhibiting HMGA2 expression. J Drug Target. 2017;25(7):653–660. doi:10.1080/1061186X.2017.132322028436711
   PubMed Web of Science ®Google Scholar
• Li C, Zou J, Zheng G, et al. MiR-30a decreases multidrug resistance (MDR) of gastric cancer cells. Med Sci Monit. 2016;22:4509–4515. doi:10.12659/MSM.898415
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu C, Luo M, et al. Chemotherapy-induced miRNA-29c/catenin-δ signaling suppresses metastasis in gastric cancer. Cancer Res. 2015;75(7):1332–1344. doi:10.1158/0008-5472.CAN-14-078725634213
   PubMed Web of Science ®Google Scholar
• Fang Q, Chen X, Zhi X. Long non-coding RNA (LncRNA) urothelial carcinoma associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b. Med Sci Monit. 2016;22:3506–3513. doi:10.12659/MSM.90068827694794
   PubMed Web of Science ®Google Scholar
• Kim H, Choi H, Lee SK. Epstein-Barr virus miR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD. Cancer Lett. 2015;356(2 Pt B):733–742. doi:10.1016/j.canlet.2014.10.02325449437
   PubMed Web of Science ®Google Scholar
• Zhu F, Wu Q, Ni Z, et al. MiR-19a/b and MeCP2 repress reciprocally to regulate multidrug resistance in gastric cancer cells. Int J Mol Med. 2018;42(1):228–236. doi:10.3892/ijmm.2018.358129568890
   PubMed Web of Science ®Google Scholar
• Wu DM, Hong XW, Wang LL, et al. MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer. Int J Biochem Cell Biol. 2018;102:59–70. doi:10.1016/j.biocel.2018.06.00729953965
   PubMed Web of Science ®Google Scholar
• Xia L, Zhang D, Du R, et al. MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123(2):372–379. doi:10.1002/ijc.2350118449891
   PubMed Web of Science ®Google Scholar
• Xing Z, Yu L, Li X, et al. Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p. Cell Biosci. 2016;6:53. doi:10.1186/s13578-016-0112-827688872
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhao D, Tan G, et al. Bufalin promotes apoptosis of gastric cancer by down-regulation of miR-298 targeting bax. Int J Clin Exp Med. 2015;8(3):3420–3428.26064232
   PubMed Web of Science ®Google Scholar
• You HY, Xie XM, Zhang WJ, et al. Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203. In Vitro Cell Dev Biol Anim. 2016;52(8):857–863. doi:10.1007/s11626-016-0044-y27142767
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang Y, Zhu Z, et al. Propofol inhibits proliferation, migration and invasion of gastric cancer cells by up-regulating microRNA-195. Int J Biol Macromol. 2018;120(Pt A):975–984. doi:10.1016/j.ijbiomac.2018.08.17330171944
   PubMed Web of Science ®Google Scholar
• Zhang F, Ma C. Kaempferol suppresses human gastric cancer SNU-216 cell proliferation, promotes cell autophagy, but has no influence on cell apoptosis. Braz J Med Biol Res. 2019;52(2):e7843. doi:10.1590/1414-431x2018784330785478
   PubMed Web of Science ®Google Scholar
• Xiang F, Pan C, Kong Q, et al. Ursolic acid inhibits the proliferation of gastric cancer cells by targeting miR-133a. Oncol Res. 2014;22(5–6):267–273. doi:10.3727/096504015X1441023848668526629938
   PubMed Web of Science ®Google Scholar
• Shekari N, Javadian M, Ghasemi M, et al. Synergistic beneficial effect of docosahexaenoic acid (DHA) and docetaxel on the expression level of matrix metalloproteinase-2 (MMP-2) and microRNA-106b in gastric cancer. J Gastrointest Cancer. 2019. doi:10.1007/s12029-019-00205-0
   Web of Science ®Google Scholar
• Mohammadian F, Pilehvar SY, Mofarrah M, et al. Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles. Artif Cells Nanomed Biotechnol. 2016;44(8):1972–1978. doi:10.3109/21691401.2015.112961526772615
   PubMed Web of Science ®Google Scholar
• Mohammadian F, Pilehvar SY, Alipour S, et al. Chrysin Alters microRNAs expression levels in gastric cancer cells: possible molecular mechanism. Drug Res (Stuttg). 2017;67(9):509–514. doi:10.1055/s-0042-11964728628924
   PubMedGoogle Scholar
• Jia J, Zhan D, Li J, et al. The contrary functions of lncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells. J Cell Mol Med. 2019;23(1):656–669. doi:10.1111/jcmm.1397030338929
   PubMed Web of Science ®Google Scholar
• Zhu C, Huang Q, Zhu H. Melatonin inhibits the proliferation of gastric cancer cells through regulating the miR-16-5p-Smad3 pathway. DNA Cell Biol. 2018;37(3):244–252. doi:10.1089/dna.2017.404029359963
   PubMed Web of Science ®Google Scholar